Pharmaceuticals Latin America

Latin America Radiopharmaceuticals Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Latin America Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Latin America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $327.1 Mn Placeholder estimate
Estimate 2025 $363.4 Mn 4% of the global market
Projected 2034 $937.1 Mn 157.9% Adds $573.7 Mn over 9 forecast years
CAGR 2025–2034 11.1% Faster than 61% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Latin America is 4% of the global market.
  • Among regions, the largest is North America at $4.23 Bn.
  • Fastest growing: APAC at 11.4% a year.
  • Latin America ranks 5th of 6 by size among regions.

Market size projection

Latin America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$573.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Radiopharmaceuticals Market market size by year, Latin America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $327.1 Mn — —
2025 (base) $363.4 Mn +$36.3 Mn —
2026 (forecast) $403.7 Mn +$40.3 Mn +11.1%
2027 (forecast) $448.5 Mn +$44.8 Mn +23.4%
2028 (forecast) $498.3 Mn +$49.8 Mn +37.1%
2029 (forecast) $553.6 Mn +$55.3 Mn +52.4%
2030 (forecast) $615.1 Mn +$61.5 Mn +69.3%
2031 (forecast) $683.4 Mn +$68.3 Mn +88.1%
2032 (forecast) $759.2 Mn +$75.9 Mn +108.9%
2033 (forecast) $843.5 Mn +$84.3 Mn +132.1%
2034 (forecast) $937.1 Mn +$93.6 Mn +157.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Latin America Radiopharmaceuticals Market Analysis at a glance
Market size, 2025$363.4 Mn placeholder estimate
Forecast, 2034$937.1 Mn placeholder estimate
Growth (CAGR), 2025–203411.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, isotope and end user (see all)
Key playersNovartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and 1 more (see all)
Active clinical trials1 in Latin AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Latin America Radiopharmaceuticals Market Analysis Executive Summary

Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.

Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).

Bar chart: Latin America Radiopharmaceuticals market size, 2024–2034, placeholder estimates. $327.1 Mn in 2024, $363.4 Mn in 2025 and $937.1 Mn in 2034, 11.1% CAGR.
Latin America Radiopharmaceuticals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Latin America Radiopharmaceuticals Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.

Competitive Landscape for Radiopharmaceuticals Market in Latin America

The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Radiopharmaceuticals Market in Latin America

Radiopharmaceuticals in Latin America: rules, payment and research

In some of the countries we cover here, medicines are approved by ANVISA (Brazil)⁠[1], ARCSA (Ecuador)⁠[2], COFEPRIS (Mexico)⁠[3], ANMAT (Argentina)⁠[4], INVIMA (Colombia)⁠[5] and ISP (Chile)⁠[6]. How care is paid for in some of these countries: the SUS (Brazil)⁠[7]; public care and IESS (Ecuador)⁠[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)⁠[9]; public care, obras sociales and prepaid plans (Argentina)⁠[10]; social health insurance (EPS) (Colombia)⁠[11]; and FONASA and ISAPREs (Chile)⁠[12]. ClinicalTrials.gov lists 1 study on Radiopharmaceuticals that is recruiting, active or about to start in Latin America.⁠[13]

[1] ANVISA. Checked 14 Nov 2026.

[2] ARCSA. Checked 14 Nov 2026.

[3] COFEPRIS. Checked 14 Nov 2026.

[4] ANMAT. Checked 19 Nov 2026.

[5] INVIMA. Checked 19 Nov 2026.

[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.

[7] CONITEC. Checked 14 Nov 2026.

[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.

[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.

[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.

[12] FONASA. Checked 19 Nov 2026.

[13] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Latin America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.

Clinical trials

1 active trial in Brazil, Mexico, Argentina, Colombia, Chile, Ecuador and Haiti

Recruiting, about to start, or running now. Counted across the 7 countries we report on in Latin America.

Top trial sponsors (worldwide)

  1. Novartis AG 19 active trials on ClinicalTrials.gov (opens in a new tab)
  2. AstraZeneca 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Eli Lilly and Company 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Fusion Pharmaceuticals Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. AC Immune (Switzerland) 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Radiopharmaceuticals in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Radiopharmaceuticals market in Latin America?
Placeholder estimate: about $363.4 Mn in 2025, rising to about $937.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Radiopharmaceuticals market in Latin America growing?
Placeholder estimate: about 11.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Radiopharmaceuticals market report cover?
The report splits the market by type (Diagnostic, Therapeutic), isotope (Lutetium-177, Actinium-225, Fluorine-18, Technetium-99m and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Radiopharmaceuticals market?
Key players include Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and GE Healthcare.
What is driving the Radiopharmaceuticals market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
How many clinical trials on Radiopharmaceuticals are running in Latin America?
1 study is recruiting, active or about to start in Latin America, counted across the 7 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
How much research is published on Radiopharmaceuticals?
PubMed lists 2,809 papers on Radiopharmaceuticals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Latin America

See all

Related on oncology

See the topic